Not a member? Register.
Intraline® is an innovative, cross-linked, hyaluronic acid based dermal filler used for wrinkle reduction, facial contouring, lip enhancement, and other facial imperfections.
It is manufactured in Sweden by Bohus BioTech AB, using hyaluronic acid sourced from France. Intraline was introduced to the UK cosmetic marketplace in October 2015.
Cross-linked, non-animal derived hyaluronic acid (sodium hyaluronate), created through a proprietary bacterial fermentation process.
Intraline is environmentally safe and contains premium medical grade, non-animal derived hyaluronic acid (HA) and a small amount of 1,4-butanediol diglycidyl ether (BDDE), less than 1ug/ml (>0.0001%), for optimal purity through cross-linking.
The product includes an innovative spherification technology developed by the Swiss researchers. It is claimed that this smoothes the traditionally angular, rhomboid molecular structure of the HA molecule. The result is a product with some of the highest molecular densities of any product on the market today, says the makers, which leads to smoother, more natural results.
No allergy test is required.
Intraline offers results that are visible for up to nine months after the initial treatment, with repeat treatment options available at six to twelve months for maintenance.
Hyaluronic acid is completely broken down within the skin over a period of months, eventually leaving no trace of the filler.
European CE mark approved as a medical device (CE0483).
Intraline should be administered by trained members of the medical profession only.
Intraline offers several formulations of their brand which include:
This product contains medium-sized molecular spheres of HA with a concentration of 20mg/ml of HA in a 1ml syringe. It treats medium to deep (moderate) wrinkles that affect the frown lines, cupid’s bow of the lips, oral commissures around the mouth and marionette lines, nasolabial folds, and for facial contouring and lip augmentation. Injections are delivered to the mid-dermal level with a 27G (gauge) needle.
This product contains large-sized molecular spheres of HA with a concentration of 20mg/ml of HA in a 1ml syringe. It treats deeper set wrinkles and facial contouring of the chin and jawline. It can also be used for lip enhancement. Injections are delivered to the mid-dermal to deep-dermal level with a 27G needle.
The newest product derivative to be launched. It is used to boost volume, optimise facial contouring, and lip enhancement. Injections are delivered to the mid-dermal and subcutaneous levels.
Launched in the Spring of 2016, this is a filler designed exclusively for the male market. This product contains large-sized molecular spheres of HA with a concentration of 20mg/ml of HA in a 1ml syringe. It is used to treat deep set wrinkles such as frown and forehead lines, as well as facial contouring of the chin and jawline and for non-surgical nose reshaping, as well as lip enhancement. Injections are delivered to the mid-dermal to deep-dermal level with a 27G needle.
Those with a known sensitivity to hyaluronic acid.
Pregnant and breast feeding women should not have any kind of dermal filler treatment.
The product must not be used near a permanent implant, or while other, on-going aesthetic treatments are taking place, such as laser or radiofrequency treatment in the same area.
Treatment should not be performed in areas where there is an active infection, acute or chronic skin disease or skin inflammation such as rashes or hives. Those with active herpes simplex (cold sore virus) should not be treated, and those who are prone to this, and have a latent case, may see activation of the virus if treated with the filler product.
Those taking any kind of anti-inflammatory medicine or aspirin, should expect more bruising and bleeding at the injection site. Those with bleeding disorders or people taking thrombolytics or anticoagulants are not suitable for treatment. A full medical history should be taken before embarking on treatment.
Intraline results claim to last between nine and twelve months after the initial treatment, depending on the treated area, with repeat treatments recommended between six and twelve months for optimal maintenance.
Expect temporary redness, pain, swelling, itching, discolouration or tenderness at the injection site. These may last for up to a week, or 14 days for treatment in the lips.
A topical anaesthetic, or numbing cream, may be administered to the treatment area to minimise any discomfort during the procedure, as the products do not contain lidocaine.
The cross-linking agent BDDE is known in rare cases to cause irritation in the skin in some people.
This depends on the area treated and the number of syringes required for treatment, as well as the individual practitioner. Expect to pay approximately £250 per 1ml of Intraline One and Intraline Two.